Doravirine, a novel NNRTI, selects for specific mutations in vitro, including mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230 and 234. The aim of this study was to examine the prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients.
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy / Soulie, Cathia; Santoro, Maria Mercedes; Storto, Alexandre; Abdi, Basma; Charpentier, Charlotte; Armenia, Daniele; Jary, Aude; Forbici, Federica; Bertoli, Ada; Gennari, William; Andreoni, Massimo; Mussini, Cristina; Antinori, Andrea; Perno, Carlo Federico; Calvez, Vincent; Ceccherini-Silberstein, Francesca; Descamps, Diane; Marcelin, Anne-Genevieve. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 75:4(2020), pp. 1026-1030. [10.1093/jac/dkz553]
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Mussini, Cristina;
2020
Abstract
Doravirine, a novel NNRTI, selects for specific mutations in vitro, including mutations at reverse transcriptase (RT) positions 106, 108, 188, 227, 230 and 234. The aim of this study was to examine the prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
